SANTA CRUZ BIOTECHNOLOGY, INC.

EBV gp350 Envelope Protein (10B5): sc-56981

SANTA CRUZ BIOTECHNOLOGY
The Power to Question

BACKGROUND

Epstein-Barr virus (EBV), also designated human herpesvirus 4 (HHV-4), is a member of the herpesvirus family and is one of the most common human viruses. EBV infects B cells and, though often asymptomatic, it can cause infectious mononucleosis, a disease characterized by fatigue, fever, sore throat and muscle soreness. EBV binds to the cell surface receptor 2 (CR2) on human B cells using its major envelope glycoprotein 350 (gp350) and, as such, the EBV gp350 Envelope Protein, also designated the EBV envelope glycoprotein complex 250/350, is crucial in mediating the initial stages of EBV infection. The EBV gp350 Envelope Protein is expressed on virion envelope as well as EBV producer cells.

REFERENCES

1. Nemerow, G.R., Houghten, R.A., Moore, M.D. and Cooper, N.R. 1989. Identification of a virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56: 369-377.
2. Emini, E.A., Schleif, W.A., Silberklang, M., Lehman, D. and Ellis, R.W. 1989. Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge. J. Med. Virol. 27: 120-123.
3. Khyatti, M., Patel, P.C., Stefanescu, I. and Menezes, J. 1991. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity. J. Virol. 65: 996-1001.
4. D'Addario, M., Ahmad, A., Morgan, A. and Menezes, J. 2000. Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNFα gene expression in monocytic cells via NFκB involving PKC, PI 3-K and tyrosine kinases. J. Mol. Biol. 298: 765-778.
5. D'Addario, M., Ahmad, A., Xu, J.W. and Menezes, J. 2000. Epstein-Barr virus envelope glycoprotein gp350 induces NFκB activation and IL-1β synthesis in human monocytes-macrophages involving PKC and PI 3-K. FASEB J. 13: 2203-2213.
6. Adachi, H., Saito, I., Horiuchi, M., Ishii, J., Nagata, Y., Mizuno, F., Nakamura, H., Yagyu, H., Takahashi, K. and Matsuoka, T. 2001. Infection of human lung fibroblasts with Epstein-Barr virus causes increased IL-1β and bFGF production. Exp. Lung Res. 27: 157-171.
7. Maruo, S., Yang, L. and Takada, K. 2001. Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J. Gen. Virol. 82: 2373-2383.
8. Prota, A.E., Sage, D.R., Stehle, T. and Fingeroth, J.D. 2002. The crystal structure of human CD21: implications for Epstein-Barr virus and C3d binding. Proc. Natl. Acad. Sci. USA 99: 10641-10646.

SOURCE

EBV gp350 Envelope Protein (10B5) is a mouse monoclonal antibody raised against EBV gp350 Envelope Protein of Epstein-Barr Virus origin.

PRODUCT

Each vial contains 100 µg IgG_1 in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

EBV gp350 Envelope Protein (10B5) is recommended for detection of EBV gp350 Envelope Protein of Epstein-Barr Virus origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Molecular Weight of EBV gp350 Envelope Protein: 113 kDa.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.